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55 days post-conception (fetal hMSCs) by nucleofection. In addition,
a combination of TGFβ receptor inhibitor— A-83-01, MEK inhibitor—
PD325901, GSK3β inhibitor — CHIR99021 and ROCK inhibitor — HA-
100 was used to enhance the efﬁciency of reprogramming (Yu et al.,
2011). Two iPS-cell lines, MSC-iPS(fetal)#1 and MSC-iPS(fetal)#2
were characterized. The expression of pluripotency-associated
markers was conﬁrmed by immunoﬂuorescence staining and
microarray-based transcriptome proﬁling (Fig. 1A and B). The
transcriptomes of MSC-iPS(fetal)#1 and MSC-iPS(fetal)#2 were
more comparable to the transcriptome of the human embryonic
stem cell line H1 (hESC H1) than to that of their parental cells with
Pearson correlations of 0.953 and 0.952 respectively (Fig. 1C and
D). In addition, the origin of the cell-types as well as the absence of
episomal plasmids in the generated iPS cells was conﬁrmed by PCR
(Fig. 1D and E). Chromosome analyses of iPS(fetal)#1 and MSC-
iPS(fetal)#2 revealed a normal male karyotype for both iPS-cell
lines (Fig. 2A). Pluripotency in vitro was also conﬁrmed by embryoid
body-based assays (Fig. 2B). Both iPS-cell lines showed high tran-
scriptome similarity with hESC H1 compared to the parental cells
based on the in silico PluriTest (Fig. 2C) (Müller et al., 2011).2. Materials and methods
2.1. Ethics statement
Fetal femur cells were derived from fetal tissue obtained at 55 days
post-conception following informed, written patient consent obtained
at the termination of pregnancy. Approval was obtained by thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Conﬁrmation of pluripotency marker expression, absence of episomal plasmids and proof of the parental cell type. A) Expression of pluripotency-associated markers in MSC-
iPS(fetal)#1 and MSC-iPS(fetal)#2 conﬁrmed by immunoﬂuorescence staining. B) mRNA expression derived from the microarray-based transcriptome proﬁling dataset. The diagram
shows the Log2 ratio of the average signal detected in the respective iPS-cell line or hESC H1 as control over the average signal detected in parental fetal hMSCs. C) Correlation values
between the transcriptomes of MSC-iPS(fetal)#1, MSC-iPS(fetal)#2, their parental primary hMSCs and hESC H1 based on expression values detected by microarray. Pearson
correlation is shown between the samples calculated with the software GenomeStudio (Illumina). D) Clustering dendrogram based on Pearson correlation depicting the similarity
between parental fetal hMSCs and the generated iPS-cell lines and hESC H1. The dendrogram was generated using the software Genome Studio (Illumina). E) DNA-ﬁngerprinting to
conﬁrm the origin of MSC-iPS(fetal)#1 and MSC-iPS(fetal)#2. Polymerase chain reaction with a microsatellite-speciﬁc primer. Acrylamide gel electrophoresis. Samples: 1: parental
fetal hMSC; 2: MSC-iPS (fetal)#1; 3: MSC-iPS(fetal)#2; 4: iPS-cell line derived from fetal hMSC, not part of this study; 5: hESC H1; 6: hESC H9.). F) Conﬁrmation of the absence of the
episomal plasmids used for reprogramming. Polymerase chain reaction using primer speciﬁc for OriP, EBNA1 or SV40LT on the episomal plasmids. Genomic DNA was used as template.
hESC H1 and hESC H9 were analyzed in parallel to rule out cross contamination. Samples: 1: parental fetal hMSC; 2: iPS-cell line derived from fetal hMSC, not part of this study; 3:
MSC-iPS(fetal)#1; 4: MSC-iPS(fetal)#2; 5: episomal plasmid DNA of pEP4 E02S ET2K; 6: no template. Size marker: GeneRuler 1 kb DNA Ladder (Life Technologies).
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2.2. Cell culture
Primary mesenchymal stromal cells were derived from human fetal
femur isolated 55 days post-conception as previously described
(Mirmalek-Sani et al., 2006). In brief, femurs were dissected from con-
nective tissue and skeletal muscle and treated with a solution of 1 mg/
ml collagenase B (Roche) in αMEM overnight at 37 °C. Isolated cells
were passed through a 70 μmnylonmesh ﬁlter (Fisher Scientiﬁc) to re-
move remaining tissue and centrifuged for 5 min at 1000 rpm. Pellets
were resuspended in αMEM, supplemented with 10% fetal bovine
serum(Life Technologies) and 1% penicillin/streptomycin (Life Technol-
ogies), and seeded in 25 cm2 asks. Cellsweremaintained in amonolayer
culture under standard conditions at 37 °C and 5% CO2. The fetal MSCs
were characterized as MSCs based on the minimal criteria described
by the International Society for Cellular Therapy (Dominici et al.,
2006). Pluripotent stem cells were cultured in a medium consisting of
Knock-Out DMEM supplemented with 20% Knockout Serum Replace-
ment, 0.1 mM β-mercaptoethanol, non-essential amino acids, L-gluta-
mine, sodium pyruvate and penicillin/streptomycin (all purchased
from Life Technologies). 8 ng/ml basic ﬁbroblast growth factor (bFGF)
(Peprotech) were added to the medium. Cell culture was carried out
at 37 °C and 5% CO2 in a humidiﬁed atmosphere. The cells were seeded
onto cell culture dishes coated with Matrigel (Becton Dickinson) when
cultured as feeder-free or onmitomycin-c inactivatedmouse embryonic
ﬁbroblasts (MEFs).
2.3. Non-viral generation of iPS-cells from fetal hMSCs
Fetal hMSCs were nucleofected with episomal plasmids using the
Human MSC (Mesenchymal Stem Cell) Nucleofector® Kit (Lonza, VPE-
1001) and the Amaxa Nucleofector II® Device (Lonza) following the
manufacturer's instructions. The combination of episomal plasmids
7F-2 was used (Yu et al., 2011) to initiate reprogramming. Primary
fetal hMSCs were expanded until passage 2, detached by trypsin, and
washed. 1 × 106 fetal hMSCs were mixed with 3 μg of pEP4 EO2S
EN2K, 3.2 μg of pEP4 EO2S ET2K, 2.4 μg of pCEP4-M2L and 100 μl
Human MSC Nucleofactor solution warmed to room temperature.
After mixing, the program U-23 of the Amaxa Nucleofector II® Device
was used to nucleofect the fetal hMSCs. Nucleofected cells were seeded
onto a 150 cm2 cell culture dish in a hMSC maintenance medium
consisting of MEM α, nucleosides, GlutaMAX™ (Life technologies),
10% fetal bovine serum (FBS) (Biochrom AG), penicillin/streptomycin
(Life Technologies) and non-essential amino acids. After 6 days of cul-
turing, the cells were trypsinized and seeded onto cell culture plates
coated with Matrigel and inactivated MEFs at a density of 6 × 104 per
well of a 6 well plate. The seeded cells were cultured in an N2B27medi-
um supplementedwith 8 ng/ml bFGF and TGFβ receptor inhibitor A-83-
01, MEK inhibitor PD325901, GSK3β inhibitor CHIR99021 and ROCK in-
hibitor HA-100 as previously described (Yu et al., 2011). The media
were changed every other day until cell colonies with hESC-like mor-
phology were visible. These colonies were mechanically isolated and
transferred to new cell culture dishes coated with Matrigel and
inactivated MEFs as described previously (Hossini et al., 2015;
Takahashi et al., 2007).
2.4. Detection of episomal plasmids in iPS-cells
To test for the absence or presence of the episomal plasmids in the
generated iPS-cells, polymerase chain reaction (PCR) using plasmid-
speciﬁc primer sequences was employed (Table 1). The following pro-
gram was used: Initial denaturation 94 °C for 5 min, denaturation
94 °C for 15 s, primer annealing 55 °C for 30 s, primer extension 68 °C
for 1 min, ﬁnal extension 68 °C for 7 min for 35 cycles followed by aﬁnal hold at 4 °C. 50 ng of the plasmid pEP4 E02S ET2Kwas used as pos-
itive control. 100 ngof genomic DNAof the respective sampleswas used
as template. The PCR productswere analyzed by agarose gel electropho-
resis on a 2% agarose gel.
2.5. DNA ﬁngerprinting analysis
The origin ofMSC-iPS(fetal)#1 andMSC-iPS(fetal)#2was conﬁrmed
by DNA ﬁngerprinting PCR with a primer speciﬁc for the microsatellite
D7S796. The primer sequences are described in Table 1. 50 ng of geno-
mic DNAwas used as template. The samples were analyzed using a pre-
viously described PCR program in a Dyad thermal cycler (BioRad)
(Megges et al., 2015). To compare the amplicon sizes of the respective
samples, the PCR products were analyzed by acrylamide gel electropho-
resis using a 4% acrylamide gel.
2.6. Embryoid body-based in-vitro test of pluripotency
MSC-iPS(fetal)#1 and MSC-iPS(fetal)#2 were cultured until con-
ﬂuent, split and transferred to a 60 mm ultra low attachment culture
(Corning) containing medium consisting of DMEM 10% FBS, sodium
pyruvate, nonessential amino acids, L-glutamine and penicillin/
streptomycin (Life Technologies) without bFGF and the medium
was changed every other day. The EBs were seeded onto gelatin-
coated cell culture dishes after 10 days and cultured further in the
same media with the same frequency of media change. After
10 days differentiated cells were stained by immunoﬂuorescence
to analyze the presence of makers of endoderm, ectoderm and
mesoderm.
2.7. Immunoﬂuorescence staining
MSC-iPS(fetal)#1 andMSC-iPS(fetal)#2 were analyzed for the pres-
ence of pluripotency-associated markers or germ-layer-speciﬁc
markers by ﬁxation for 20 min in 4% paraformaldehyde in phosphate-
buffered saline (PBS) at room temperature. Subsequently the cells
were washed using PBS and incubated in 1% Triton X-100 (Sigma) in
PBS at room temperature for 10 min. Next, the cells were blocked by
incubation in 10% FBS in 0.1% Triton X-100 in PBS. The cells were incu-
bated with the necessary concentration of primary antibody at 4 °C over-
night. This was followed by three washes with PBS and a 1 h-incubation
with the secondary antibody at room temperature. Next, the cells were
washed three times with PBS and incubated in 200 ng/ml DAPI
(Invitrogen). The types and concentrations of primary and secondary an-
tibodies that were used to characterize MSC-iPS(fetal)#1 and MSC-
iPS(fetal)#2 were previously described (Megges et al., 2015). The immu-
noﬂuorescence staining was visualized with a confocal microscope type
LSM510 (Zeiss).
2.8. Conﬁrmation of pluripotency by PluriTest
Pluripotency of the generated iPS-cells was tested with the in silico
test, PluriTest —www.pluritest.org. (Müller et al., 2011).
2.9. Microarray-based transcriptome analysis
Total RNA was extracted using the Universal RNA Puriﬁcation Kit
(Roboklon). 500 ng of RNA was used to generate biotin-labeled cRNA
using a linear ampliﬁcation kit (Ambion). The cRNA samples were proc-
essed with the Illumina BeadStation 500 platform (Illumina) following
the manufacturer's instructions. HumanHT-12 v4.0 Gene Expression
BeadChips were used to hybridize the cRNA samples. The gene expres-
sion module of the software Genome Studio (Illumina) was used to
analyze and process the gene expression data detectedwith this system
and to generate the clustering dendrogram.
Fig. 2. Karyotype analysis and conﬁrmation of pluripotency in vitro and by PluriTest. A) Chromosomal analysis based on GTG-banding revealed a normal male karyotype in the iPS-cells
generated from fetal hMSC in 20 metaphases. B) Conﬁrmation of pluripotency in vitro by embryoid body based differentiation. MSC-iPS(fetal)#1 and MSC-iPS(fetal)#2 were able to
differentiate into cells expressing ectodermal markers β-TubulinIII (TUJ1) and NESTIN, into cell expressing mesodermal markers Smooth-Muscle-Actin (SMA) and Brachyury (T) and
into cells expressing the endodermal markers SOX17 and α Fetoprotein (AFP). Immunoﬂuorescence staining. Red: expression of marker. Blue: DAPI visualizing the nuclei.
C) Conﬁrmation of pluripotency with the bioinformatics tool PluriTest based on the transcriptome detected by microarray. Parental fetal hMSC with their respective iPS-cells and hESC
H1 was compared. A dendrogram based on Pearson correlation of the calculated pluripotency between the samples (left) and the comparison of the calculated pluripotency measure
based on PluriTest. (www.pluritest.org) (Müller et al., 2011).
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Table 1
Sequences of the primers used forDNA ﬁngerprinting and PCR-based detection of episom-
al plasmids.
Gene Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
D7S796 TTTTGGTATTGGCCATCCTA GAAAGGAACAGAGAGACAGGG
OriP TTCCACGAGGGTAGTGAACC TCGGGGGTGTTAGAGACAAC
EBNA ATCGTCAAAGCTGCACACAG CCCAGGAGTCCCAGTAGTCA
SV40LT AGTTTGTGCCAGGGTTTTTG ACTTCACCTTCCCTCCAACC
132 M. Megges et al. / Stem Cell Research 16 (2016) 128–1322.10. Karyotype analysis
The karyotype of 20 metaphases of MSC-iPS(fetal)#1 and MSC-
iPS(fetal)#2were analyzed by GTGbanding by the HumanGenetic Cen-
tre, Berlin, Germany.
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